Myeloma minimal residual disease testing in the United States: Evidence of improved standardization

Схожие документы

• Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
  по: Flanders, Aaron, et al.
  Опубликовано: (2013)
• Minimal residual disease in multiple myeloma: bringing the bench to the bedside
  по: Mailankody, Sham, et al.
  Опубликовано: (2015)
• Introduction to Multiple Myeloma Special Issue: The Flow Cytometric Detection of Minimal Residual Disease
  по: Preffer, Frederic I., et al.
  Опубликовано: (2016)
• Assessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach
  по: Rawstron, Andy C., et al.
  Опубликовано: (2015)
• Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models
  по: Hill, Elizabeth, et al.
  Опубликовано: (2020)